Lipid-lowering properties of TAK-475, a squalene synthase inhibitor, in vivo and in vitro.
about
A cholesterol biosynthesis inhibitor blocks Staphylococcus aureus virulenceHuman isoprenoid synthase enzymes as therapeutic targetsIncreased cholesterol biosynthesis and hypercholesterolemia in mice overexpressing squalene synthase in the liverPlasma cholesterol-lowering and transient liver dysfunction in mice lacking squalene synthase in the liverA Genomic DNA Reporter Screen Identifies Squalene Synthase Inhibitors That Act Cooperatively with Statins to Upregulate the Low-Density Lipoprotein ReceptorExploration of Peptide Inhibitors of Human Squalene Synthase through Molecular Modeling and Phage Display Technique.Recent developments in the treatment of atherosclerosis.Human cholesterol metabolism and therapeutic molecules.Advancing therapy for hypercholesterolemia.New treatments on the horizon for familial hypercholesterolemia.Role of squalene synthase in prostate cancer risk and the biological aggressiveness of human prostate cancer.Lapaquistat acetate, a squalene synthase inhibitor, changes macrophage/lipid-rich coronary plaques of hypercholesterolaemic rabbits into fibrous lesions.Identification and prioritization of novel anti-Wolbachia chemotypes from screening a 10,000-compound diversity library.Differential Regulation of Gene Expression by Cholesterol Biosynthesis Inhibitors That Reduce (Pravastatin) or Enhance (Squalestatin 1) Nonsterol Isoprenoid Levels in Primary Cultured Mouse and Rat HepatocytesEP2306 and EP2302, two novel squalene synthase inhibitors, stimulate endothelial nitric oxide synthase expression in cultured endothelial cells.Molecular docking studies to map the binding site of squalene synthase inhibitors on dehydrosqualene synthase of Staphylococcus aureus.K45R variant of squalene synthase increases total cholesterol levels in two study samples from a French Canadian population.Anti-inflammatory and cytoprotective effects of a squalene synthase inhibitor, TAK-475 active metabolite-I, in immune cells simulating mevalonate kinase deficiency (MKD)-like condition.PCSK9 as a therapeutic target of dyslipidemia
P2860
Q24650591-36AA8BCF-B45C-41D1-8C06-D3474EAB8E1FQ26822639-6B83F78C-88F3-4199-8BEE-864915ED816BQ28243492-9533B0AA-89CC-45EC-9BAD-D27E763CA068Q28258554-359FA103-F620-4D15-84A0-A78764C9CF0DQ33724316-6E38E667-41A1-47EB-A686-B3ADD56CC72FQ35800044-F9C6BB31-9232-4F70-B223-329424DAF2CBQ36434617-D76BCCC9-F41C-46C4-9309-B2A49D318991Q37047547-7C044DDC-E0AA-4AD7-B8F4-EE6584678045Q37761373-2FF94450-B809-499F-810B-64D6D5FEAD0CQ38063288-E7C2D422-3695-4446-9D08-32A4974BD485Q39356134-E1313935-CCB2-48F3-9CAB-A0FA72453446Q39873548-F51BD56C-F136-4ED1-A3B1-35B9107FAD0DQ41678406-0F8E56AF-2291-4F10-B3DC-6B8089378061Q41888201-FE6B89FF-839A-4A44-8761-58245A649CF6Q42519931-EFCED0CE-BE69-48A3-9EF7-73F0FB43C499Q42964671-654A0F75-7917-4955-974B-07B2A702A381Q46693946-61B2C55A-CA0C-4EF4-AC62-5B5F7FD5E417Q51480545-7E99A543-ADA9-48EC-8467-67389275C261Q57268596-081360A7-3A16-4F66-BD6E-C81187E52E15
P2860
Lipid-lowering properties of TAK-475, a squalene synthase inhibitor, in vivo and in vitro.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Lipid-lowering properties of T ...... hibitor, in vivo and in vitro.
@en
type
label
Lipid-lowering properties of T ...... hibitor, in vivo and in vitro.
@en
prefLabel
Lipid-lowering properties of T ...... hibitor, in vivo and in vitro.
@en
P2093
P2860
P356
P1476
Lipid-lowering properties of T ...... hibitor, in vivo and in vitro.
@en
P2093
Eiichiro Ishikawa
Hidefumi Yukimasa
Ryuichi Tozawa
Tomoyuki Nishimoto
Yasuo Sugiyama
Yoshimi Imura
Yuichiro Amano
P2860
P304
P356
10.1038/SJ.BJP.0705332
P407
P577
2003-07-01T00:00:00Z